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Background: Dexamethasone intravitreal implant 0.7 mg (DEX 0.7) was approved for treatment of diabetic macular
edema (DME) after demonstration of its efficacy and safety in the MEAD registration trials. We performed subgroup
analysis of MEAD study results to evaluate the efficacy and safety of DEX 0.7 treatment in patients with previously
treated DME.
Methods: Three-year, randomized, sham-controlled phase 3 study in patients with DME, best-corrected visual acuity
(BCVA) of 34–68 Early Treatment Diabetic Retinopathy Study letters (20/200–20/50 Snellen equivalent), and central
retinal thickness (CRT) ≥300 μm measured by time-domain optical coherence tomography. Patients were randomized
to 1 of 2 doses of DEX (0.7 mg or 0.35 mg), or to sham procedure, with retreatment no more than every 6 months. The
primary endpoint was ≥15-letter gain in BCVA at study end. Average change in BCVA and CRT from baseline during
the study (area-under-the-curve approach) and adverse events were also evaluated. The present subgroup analysis
evaluated outcomes in patients randomized to DEX 0.7 (marketed dose) or sham based on prior treatment for DME at
study entry.
Results: Baseline characteristics of previously treated DEX 0.7 (n = 247) and sham (n = 261) patients were similar. In the
previously treated subgroup, mean number of treatments over 3 years was 4.1 for DEX 0.7 and 3.2 for sham, 21.5 % of
DEX 0.7 patients versus 11.1 % of sham had ≥15-letter BCVA gain from baseline at study end (P = 0.002), mean average
BCVA change from baseline was +3.2 letters with DEX 0.7 versus +1.5 letters with sham (P = 0.024), and mean average
CRT change from baseline was −126.1 μm with DEX 0.7 versus −39.0 μm with sham (P < 0.001). Cataract-related adverse
events were reported in 70.3 % of baseline phakic patients in the previously treated DEX 0.7 subgroup; vision gains were
restored following cataract surgery.
Conclusions: DEX 0.7 significantly improved visual and anatomic outcomes in patients with DME previously treated
with laser, intravitreal anti-vascular endothelial growth factor, intravitreal triamcinolone acetonide, or a combination of
these therapies. The safety profile of DEX 0.7 in previously treated patients was similar to its safety profile in the total
study population.
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Diabetic macular edema (DME), a common cause of
vision loss, is estimated to affect 21 million individuals
worldwide [1]. The pathogenesis of DME is multifactorial
and not completely understood, but inflammation has a
key role [2, 3]. Expression of inflammatory mediators
including vascular endothelial growth factor (VEGF),
intercellular adhesion molecule-1, interleukin-6, and
monocyte chemotactic protein-1 [4], retinal leukostasis
[5], and changes in vascular endothelial cell tight junction
proteins [6] are involved in the breakdown of the blood-
retinal barrier that leads to DME.
Treatment options for fovea-involved DME with vision
loss include laser, intravitreal anti-VEGF, and intravitreal
corticosteroids. Focal/grid laser photocoagulation of leak-
ing microaneurysms and areas of diffuse capillary bed
leakage reduces the risk of moderate vision loss in DME
[7], but it is often ineffective in restoring lost vision [8].
Anti-VEGF treatment with ranibizumab is more effective
than laser in improving vision in patients with DME
[9, 10], and anti-VEGF injections have become preferred
first-line treatment for many patients [11]. The dosing fre-
quency of anti-VEGF may be a treatment burden, how-
ever, as visual gains are most pronounced when monthly
dosing is used (for example, in the phase 3 RISE/RIDE tri-
als) [12]. Furthermore, DME in some patients may be
nonresponsive or poorly responsive to anti-VEGF treat-
ment. In the RISE/RIDE trials, approximately 40 % of
patients failed to achieve BCVA of 20/40 or better and
over 50 % of patients failed to achieve a ≥15-letter gain in
BCVA after 2 years of monthly ranibizumab 0.5 mg injec-
tions [12]. Additional treatment options/strategies are
needed for patients with DME who fail to achieve sig-
nificant improvement in visual acuity with laser and/or
anti-VEGF therapy.
Corticosteroids are a rational treatment for DME
because they block the expression of VEGF and other in-
flammatory mediators of DME [13], inhibit leukostasis [14],
improve the barrier function of endothelial cell tight junc-
tions [15], and decrease vascular leakage [14]. Intravitreal
injections of triamcinolone acetonide, used off label to treat
DME, improve vision in some patients [16]. The most
frequent side effects of triamcinolone acetonide treatment
are increases in intraocular pressure (IOP) and cataract
[16]. In the DRCR.net Protocol I study, triamcinolone
acetonide and ranibizumab were similarly effective when
combined with laser treatment in pseudophakic eyes [17].
Dexamethasone is a corticosteroid with more potent
anti-inflammatory activity than triamcinolone acetonide,
but the half-life of dexamethasone in the vitreous is
short (<4 h) [18]. A sustained-release dexamethasone
implant was developed to reduce the need for frequent
intravitreal injections. Dexamethasone intravitreal implant
(DEX implant, Ozurdex; Allergan plc, Irvine, CA) is abiodegradable implant that provides sustained, localized re-
lease of dexamethasone to the posterior segment. Dexa-
methasone is released over a period of up to 6 months as
the copolymer matrix of the implant degrades into lactic
acid and glycolic acid, which are subsequently metabolized
to carbon dioxide and water [19, 20]. In 2 randomized,
multicenter, sham-controlled phase III clinical trials evalu-
ating DEX implant in patients with DME (the MEAD
study), an average of 4 to 5 injections of DEX implant
0.7 mg or 0.35 mg over 3 years provided clinically signifi-
cant visual and anatomic improvements compared with
sham procedure [21]. The safety profile of the implant was
favorable. Steroid-induced cataract and increases in IOP
occurred as expected, but the IOP increases were usually
controlled with topical medication, and only 1 patient in
each DEX implant group required glaucoma incisional sur-
gery to control a steroid-induced increase in IOP [21].
These results supported the recent US Food and Drug
Administration approval of DEX implant 0.7 mg for treat-
ment of DME in adult patients.
The present analysis was undertaken to evaluate out-
comes of DEX implant 0.7 mg treatment in the subset of
patients within the MEAD study who were enrolled with
DME that had been previously treated with laser and/or
medical therapy. Subgroup analysis evaluated efficacy
and safety results in subgroups defined by prior treat-
ment of DME in the study eye at baseline.
Methods
The subgroup analysis used pooled data from 2 random-
ized, multicenter, masked, sham-controlled, 3-year, phase 3
clinical trials with identical protocols that evaluated the
safety and efficacy of DEX implant for treatment of DME.
The trials (registered as NCT00168337 and NCT00168389
at ClinicalTrials.gov) were conducted at 131 sites in 22
countries from February 2005 to June 2012. The trials were
carried out in accordance with the tenets of the Declar-
ation of Helsinki and were compliant with the Health
Insurance Portability and Accountability Act of 1996. An
institutional review board or independent ethics committee
(105 in total) approved the study protocol at each site, and
all patients provided written informed consent. The study
protocol was described in detail previously [21] and is sum-
marized here.
Study participants
Adult patients with diabetes mellitus and vision loss sec-
ondary to fovea-involved macular edema associated with
diabetic retinopathy were enrolled. Key eligibility criteria
for study eyes included BCVA between 34 and 68 letters
(20/200 and 20/50 Snellen equivalent) measured with the
ETDRS method, central retinal thickness (CRT) in the
1 mm central macular subfield ≥300 μm measured by
time-domain optical coherence tomography (OCT) on the
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Dublin, CA) machine, and either documented history of
prior treatment of DME with laser, anti-VEGF, or steroid,
or the patient had refused laser, or the investigator
believed that the patient would not benefit from laser.
Patients with uncontrolled diabetes (glycosylated hemoglobin
[HbA1c] >10 %), a history of a marked steroid-induced
increase in IOP in either eye, or current or planned use of
systemic steroids were excluded. Key exclusion criteria for
study eyes included intravitreal anti-VEGF treatment
within 3 months of study entry, history of intravitreal
steroid other than triamcinolone acetonide, intravitreal
triamcinolone acetonide or periocular depot of steroid
within 6 months of study entry, intraocular laser or inci-
sional surgery within 90 days of study entry, glaucoma,
ocular hypertension (untreated IOP >23 mm Hg, IOP
>21 mm Hg treated with 1 antiglaucoma medication, or
use of ≥2 antiglaucoma medications), aphakia or an an-
terior chamber intraocular lens, history of pars plana
vitrectomy, and active iris or retinal neovascularization.
For patients with both eyes eligible, the eye with the shorter
duration of macular edema was selected as the study eye.Intervention and visit schedule
At baseline, 1048 patients were randomized in a 1:1:1 ratio
to treatment with DEX implant 0.7 mg, DEX implant
0.35 mg, or sham procedure. A single-use applicator sys-
tem was used to place DEX implant into the vitreous of
the study eye through the pars plana [22]. In the sham
procedure, a needleless applicator was pressed against the
conjunctiva of the study eye. Patients were seen at out-
comes assessment visits every 1.5 months during the first
year of the study and every 3 months during the second
and third year, as well as at safety visits 1, 7, and 21 days
after each study treatment or retreatment. The final visit
was at month 36 (or month 39 for patients treated at
month 36 after a protocol amendment allowing treatment
at month 36). Eligibility for retreatment was evaluated
every 3 months starting at month 6. Patients were eligible
for retreatment if it had been at least 6 months since the
previous study treatment, there was evidence of residual
edema on OCT (e.g., CRT >225 μm), and in the judgment
of the investigator, retreatment would not put the patient
at significant risk. The retreatment interval of ≥6 months
was selected based on data from a phase 2 study [19]
showing that the effects of DEX implant lasted up to
6 months after the intravitreal injection.
No concomitant treatments for macular edema in the
study eye were allowed during the study. Patients were
required to be withdrawn from the study prior to receiv-
ing any escape therapy (medical, laser, or surgical treat-
ment for macular edema) in the study eye. Systemic
steroid treatment was prohibited.Outcome assessments and endpoints
Efficacy outcome measures included BCVA by the ETDRS
method at each study visit and time-domain OCT (Stratus
OCT2 or OCT3) every 3 months. OCT images were eval-
uated at a central reading center (University of Wisconsin
Fundus Photograph Reading Center, Madison, WI, USA)
by certified operators masked to study treatment. Safety
outcome measures included adverse events and IOP.
The primary efficacy endpoint was the percentage of
patients achieving ≥15-letter gain in BCVA from baseline
in the study eye at the end of the study. Other predefined
efficacy outcomes in the study eye included average
change in BCVA from baseline during the study deter-
mined with an area-under-the-curve (AUC) approach,
time to ≥15-letter gain in BCVA from baseline, and aver-
age change in CRT from baseline during the study by
OCT (AUC approach). The AUC approach to analysis of
BCVA and CRT data takes into account all measure-
ments during the study period, and the average change
in BCVA during the study, evaluated with the AUC
approach, was used as the primary endpoint of the
study for European regulatory authorities.
Data analysis
All subgroup analyses used data for patients in the
DEX implant 0.7 mg (marketed dose) and sham treat-
ment groups. Efficacy subgroup analysis based on any
prior treatment, prior laser treatment, and no prior
laser treatment was included in the statistical plan for
the study. Other subgroup analysis based on prior treat-
ment with intravitreal triamcinolone acetonide, prior
treatment with anti-VEGF, and prior treatment with a
combination of ≥2 types of therapy among laser, intra-
vitreal triamcinolone acetonide, and anti-VEGF, was
post hoc and exploratory.
Efficacy outcomes were evaluated in the intent-to-treat
population of all randomized patients. In the analysis of
the percentage of patients achieving ≥15-letter gain in
BCVA from baseline at study end, missing values were
imputed with the last-observation-carried-forward method.
The analyses of average change in BCVA and CRT from
baseline during the study (AUC approach) and time-to-
event data used observed data.
Baseline characteristics of the previously treated
patient subgroup were summarized with descriptive
statistics. The percentage of patients with ≥15-letter
BCVA improvement from baseline was analyzed with
the Cochran-Mantel-Haenszel general association test
stratified by study, with the 95 % confidence interval of
the between-group difference constructed using normal
approximation for binary variables. The average change
in BCVA or CRT from baseline during the study (AUC
approach) was analyzed with analysis of covariance
models with treatment and study as fixed effects and
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differences and 95 % confidence intervals were from
least-squares means. The Kaplan-Meier method was
used to analyze time to ≥15-letter BCVA improvement
from baseline, and cumulative response rates were
compared using the log-rank test. Safety outcomes were
evaluated in the safety population of all patients who
received study treatment.
Statistical analysis was performed with SAS version 9.3
(SAS Institute Inc., Cary, NC, USA) using a 2-sided
alpha level of 0.05.
Results
The previously treated subgroup represented 70.4 %
(247/351) of patients in the DEX implant 0.7 mg group
and 74.6 % (261/350) of patients in the sham group.
Baseline demographic and clinical characteristics of pre-
viously treated patients were similar for patients in the
DEX implant 0.7 mg and sham groups (Table 1). Over
90 % of patients in the previously treated subgroup had
received macular laser in the study eye for DME prior toTable 1 Baseline characteristics of previously treated patients
and study eyes (intent-to-treat population)
Characteristic DEX 0.7 Sham
n = 247 n = 261
Patients
Mean age (SD), yr 63.0 (8.3) 63.0 (9.1)
Male, n (%) 150 (60.7) 168 (64.4)
Caucasian, n (%) 188 (76.1) 192 (73.6)
Mean diabetes duration (SD), yr 16.4 (8.7) 16.2 (9.7)
Type 2 diabetes, n (%) 220 (89.1) 238 (91.2)
Mean HbA1c (SD), % 7.5 (1.1) 7.5 (1.0)
≤8 %, n (%) 168 (68.0) 189 (72.4)
Mean DME duration (SD), mo 27.3 (26.3) 31.9 (28.6)
Study eyes
Lens status, n (%)
Phakic 182 (73.7) 179 (68.6)
Pseudophakic 65 (26.3) 82 (31.4)
Mean BCVA (SD), ETDRS letters 55.2 (9.6) 56.1 (9.1)
Mean CRT (SD), μm 478 (153) 472 (131)
Prior DME treatment, n (%) 247 (100) 261 (100)
Laser 231 (93.5) 243 (93.1)
Intravitreal triamcinolone acetonide 58 (23.5) 61 (23.4)
Intravitreal anti-VEGF 25 (10.1) 26 (10.0)
At least 2 of the 3 types of treatment 61 (24.7) 57 (21.8)
No prior DME treatment, n (%) 0 (0) 0 (0)
BCVA best-corrected visual acuity, CRT central retinal thickness, DEX 0.7
dexamethasone intravitreal implant 0.7 mg, DME diabetic macular edema,
ETDRS Early Treatment Diabetic Retinopathy Study, HbA1c glycosylated
hemoglobin, SD standard deviation, VEGF vascular endothelial growth factorstudy entry, whereas 23 % had received intravitreal tri-
amcinolone acetonide, and 10 % had received intravitreal
anti-VEGF (Table 1). Approximately 23 % of patients in
the previously treated subgroup had received at least 2
of these 3 types of therapy for DME in the study eye
prior to study entry (Table 1). The median duration of
DME in previously treated patients was 20 months in
the DEX implant 0.7 mg group and 24 months in the
sham group.
Three-year study completion rates in the previously
treated subgroup were 67.6 % (167/247) for patients in the
DEX implant 0.7 mg group and 43.7 % (114/261) for
patients in the sham group, similar to those in the overall
study population (64.1 % and 43.4 %, respectively). Within
the previously treated subgroup, lack of efficacy led to
discontinuation of 5.7 % of patients treated with DEX
implant 0.7 mg and 24.5 % of patients treated with sham,
while adverse events led to discontinuation of 12.1 % of
patients treated with DEX implant 0.7 mg and 11.1 % of
patients treated with sham. Only 2.8 % and 5.0 % of previ-
ously treated patients in the DEX implant 0.7 mg and
sham groups, respectively, were lost to follow-up. The
mean (standard deviation) number of treatments received
over 3 years was 4.1 (1.9) in previously treated patients in
the DEX implant 0.7 mg group and 3.2 (2.2) in previously
treated patients in the sham group.
Efficacy outcomes were consistently significantly better
with DEX implant 0.7 mg than sham in the previously
treated subgroup (Table 2). The percentage of previously
treated patients achieving ≥15-letter gain in BCVA from
baseline at the year 3 or final study visit (primary efficacy
endpoint) was 21.5 % in the DEX implant 0.7 mg group
versus 11.1 % in the sham group (P = 0.002), though the
results in the DEX implant 0.7 mg group may have varied
based on the type of prior treatment received. The per-
centage of patients achieving ≥15-letter gain was
27.6 % for patients previously treated with steroids,
28.0 % for patients previously treated with anti-VEGF,
and 21.2 % for patients previously treated with laser
(Table 3). Previously treated patients in the DEX
implant 0.7 mg group also demonstrated greater average
improvement in BCVA and CRT from baseline during the
study (AUC approach) compared with previously treated
patients in the sham group. Mean average improvement
in BCVA was +3.2 letters in the DEX implant 0.7 mg
group versus +1.5 letters in the sham group (P = 0.024),
and mean average improvement in CRT was −126 μm in
the DEX implant 0.7 mg group versus −39 μm in the
sham group (P < 0.001). Efficacy outcomes were better
with DEX implant 0.7 mg than sham in patient subgroups
defined by previous treatment with laser, intravitreal
triamcinolone acetonide, or anti-VEGF (Table 3), or by a
combination of at least 2 of these 3 types of therapy
(Table 4).
Table 2 Key efficacy endpoints in previously treated patients
Endpoint DEX 0.7 Sham Mean
Difference
P Value
n = 247 n = 261
Patients with BCVA ≥15-letter improvement from baseline at study end, % 21.5 11.1 10.3 0.002b
Mean BCVA average change from baseline during the study (SD), lettersa +3.2 (8.7) +1.5 (7.5) 1.6 0.024c
Mean CRT average change from baseline during the study (SD), μma −126 (131) −39 (121) −85 <0.001c
aArea-under-the-curve approach
bBased on the Cochran-Mantel-Haenszel general association test stratified by study
cBased on an analysis of covariance model with treatment and study as factors and the baseline value as a covariate
BCVA best-corrected visual acuity, CRT central retinal thickness, DEX 0.7 dexamethasone intravitreal implant 0.7 mg; SD standard deviation
Augustin et al. BMC Ophthalmology  (2015) 15:150 Page 5 of 9Within the subgroup of patients with any previous treat-
ment for DME, patients in the DEX implant 0.7 mg group
showed significantly earlier ≥15-letter gain in BCVA from
baseline compared with patients in the sham group (P <
0.001, Fig. 1). Separation of the cumulative response rate
curves was evident before the first efficacy visit. The time
to the 10th percentile cumulative response was 41 days
with DEX 0.7 mg versus 184 days with sham.
The safety profile of DEX implant 0.7 mg in previously
treated patients was similar to its safety profile in the
total study population [21]. The most common adverse
events in the previously treated subgroup were steroid-
related increases in IOP and cataract (Table 5). Within
the previously treated subgroup, cataract-related adverse
events were reported in 70.3 % of baseline phakic
patients in the DEX implant 0.7 mg group. In patients
who had cataract-related adverse events, vision gains
were restored following cataract surgery (Fig. 2).
Discussion
Preplanned subgroup analysis of the MEAD study
results showed that DEX implant 0.7 mg significantly
improved visual and anatomic outcomes in patients with
a history of previous medical or laser treatment for
DME. Exploratory analysis of outcomes in patient sub-
groups defined by previous treatment of DME with
intraocular triamcinolone acetonide, anti-VEGF, or at
least 2 types of therapy (among laser, intraocular steroid,
and anti-VEGF) also showed benefit of DEX implant
0.7 mg treatment relative to sham. Safety findings for
DEX implant in the previously treated subgroup were
similar to those in the total patient population.Table 3 Efficacy in Subgroups Defined by Type of Previous Treatme
Endpoint
Patients with BCVA ≥15-letter improvement from baseline at study end, %
Mean BCVA average change from baseline during the study (SD), lettersa
Mean CRT average change from baseline during the study (SD), μma
aArea-under-the-curve approach
BCVA best-corrected visual acuity, CRT central retinal thickness, DEX 0.7 dexamethasMost of the patients enrolled in the MEAD study had
persistent edema and vision loss despite prior therapy.
Because the study was sham controlled, investigators
were unlikely to allow patients who were adequately
responsive to available treatments to enter the study.
Therefore, the previously treated subgroup represented
a difficult-to-treat population. Among the previously
treated patients in the DEX implant 0.7 mg and sham
groups, the mean duration of edema at study entry was
approximately 2.5 years, and over 90 % had been
treated previously with laser for DME in the study eye.
Results of the subgroup analysis demonstrated the
efficacy of DEX implant in this difficult-to-treat popula-
tion. Efficacy outcomes in the previously treated sub-
group of patients were very similar to those in the total
study population [21]. Within the previously treated
subgroup, the percentage of patients with ≥15-letter
BCVA gain at the end of the study was significantly
higher with DEX implant 0.7 mg than with sham, and
the average change in BCVA and CRT from baseline
during the study (AUC approach) was significantly
greater with DEX implant 0.7 mg than with sham.
In the total study population, analysis of BCVA changes
from baseline at each visit showed diminished treatment
effect by 6 months postinjection [21]. Furthermore, in a
recent prospective study evaluating visual and anatomic
outcomes after DEX implant treatment in retinal diseases
including DME, the optimal interval for DEX implant
retreatment, based on efficacy and safety outcomes, was
determined to be 20 weeks (4 to 5 months) [23]. Thus, it
is likely that more frequent dosing of DEX implant than
the ≥6-month intervals used in the MEAD study wouldnt Received
Prior Steroid Prior Anti-VEGF Prior Laser
DEX 0.7 Sham DEX 0.7 Sham DEX 0.7 Sham
n = 58 n = 61 n = 25 n = 26 n = 231 n = 243
27.6 8.2 28.0 7.7 21.2 11.9
+4.9 (7.4) −0.6 (8.6) +4.2 (8.8) +1.6 (7.6) +3.1 (8.7) +1.6 (7.5)
−121 (150) −30 (135) −130 (95) −42 (123) −123 (130) −39 (121)
one intravitreal implant 0.7 mg, SD standard deviation
Table 4 Efficacy in Patients With at Least 2 Types of Previous Treatmenta
Endpoint DEX 0.7 Sham Mean Difference
n = 61 n = 57 (95 % CI)
Patients with BCVA ≥15-letter improvement from baseline at study end, % 26.2 8.8 17.5 (4.2, 30.7)c
Mean BCVA average change during the study, lettersb 4.0 −0.3 3.8 (1.1, 6.5)d
Mean CRT average change during the study, μmb −108 −26 −111 (−154, −69)d
aTypes of previous treatment were macular laser, intravitreal triamcinolone acetonide, and intravitreal anti-VEGF
bArea-under-the-curve approach
cBased on the Cochran-Mantel-Haenszel general association test stratified by study
dBased on an analysis of covariance model with treatment and study as factors and the baseline value as a covariate
BCVA best-corrected visual acuity, CI confidence interval, CRT central retinal thickness, DEX 0.7 dexamethasone intravitreal implant 0.7 mg, VEGF vascular
endothelial growth factor
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over time and at study end, and the MEAD study out-
comes may underestimate the true value of DEX implant
in DME.
Efficacy of DEX implant in previously treated patients
in the MEAD study, reported here, is consistent with the
results of previous small studies of DEX implant treat-
ment in patients with persistent DME despite prior ther-
apy [24, 25]. In those studies, DEX implant improved
BCVA and foveal thickness in patients with edema that
was refractory to laser, intraocular steroid, or anti-VEGF
treatment [24, 25]. Although anti-VEGF is often used as
first-line treatment of DME, not all patients respond to
anti-VEGF. The number of patients in the MEAD study
who had been previously treated with anti-VEGF was
small, but the subgroup analysis results nonetheless
suggest that DEX implant effectively improved BCVA
and CRT in patients previously treated with anti-VEGF.
These results are consistent with the previous report of
DEX implant effectiveness in the treatment of DME
that had not responded to 3 monthly injections of
intravitreal bevacizumab anti-VEGF therapy [25]. The
multifactorial nature of DME [2] may explain why some
patients are refractive to anti-VEGF treatment but
respond to steroids.Fig. 1 Survival analysis of the time to ≥15-letter improvement in best-correct
comparing cumulative response rate curves over time). DEX 0.7 = dexamethaThe most common adverse event associated with
DEX implant treatment in the MEAD study was cata-
ract [21]. Although phakic eyes are at high risk of cata-
ract progression after multiple DEX implant injections,
treatment with DEX implant may be justifiable in
phakic patients who have not responded to other treat-
ment, because persistent DME can lead to irreversible
vision loss, whereas patients who develop cataract dur-
ing DEX implant treatment recover vision gain after
cataract extraction. The analysis of BCVA gain in
patients after cataract surgery showed a trend for
greater improvement in BCVA with longer follow-up.
These results suggest that the recovery time from cataract
surgery for patients who underwent cataract extraction
near (e.g., within 3 months of) the end of the study may
not have been long enough for them to regain treatment
benefit by the study end. Timely extraction of cataracts
is recommended during DEX implant treatment to
maximize visual gains.
There are several limitations of the present analysis.
Although patients could be categorized by their previ-
ous treatment for DME, information regarding the
number of prior laser, anti-VEGF, and steroid treat-
ments received by each patient was not collected.
Because the study began in 2004, relatively few patientsed visual acuity (BCVA) from baseline. *P < 0.001 vs sham (log-rank test
sone intravitreal implant 0.7 mg
Table 5 Incidence of Adverse Events (Safety Population)
Previously Treated Patients Total Study Population
Incidence, % DEX 0.7 Sham DEX 0.7 Sham
n = 247 n = 261 n = 347 n = 350
Serious ocular AE 6.9 0.8 6.9 1.1
IOP-related AEa 38.1 4.6 36.0 5.1
Cataract-related AE (incidence in phakic eyes) 70.3 20.1 67.9 20.4
aAny adverse event (AE) related to increased intraocular pressure or glaucoma
AE adverse event, DEX 0.7 dexamethasone intravitreal implant 0.7 mg, IOP intraocular pressure
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Also, patients with prior pars plana vitrectomy, a surgical
option for DME in some patients, were excluded. How-
ever, it has been reported that DEX implant is also effect-
ive in the treatment of DME in eyes with prior vitrectomy
[26, 27]. The study completion rates were relatively low,
especially in the sham group, because of the MEAD study
design requirement for patients to exit the study before
receiving any escape therapy [21]. This study requirement
prevented any confounding effects of concomitant therapy
from influencing the study results, but also led to an in-
creased rate of patient discontinuations, which can bias
study results if the remaining patients are not representa-
tive of the larger randomized patient population. Among
previously treated patients who received DEX implant
0.7 mg, the discontinuation rate was approximately 32 %,
compared with discontinuation rates of approximately
20 %–30 % reported in 3-year studies of medical therapy
in DME that allowed patients to receive rescue therapyFig. 2 Mean average best-corrected visual acuity (BCVA) change from baselin
treated patients with cataract-related adverse events (AEs) in the dexamethas
number of patientsand continue in the study [28, 29]. Patients treated with
sham procedure discontinued earlier and at a higher rate
than patients treated with DEX implant because of lack of
efficacy and need for escape therapy. Appropriate sta-
tistical methods were used to deal with patient dropouts
and missing values in the data analysis.
Conclusion
This subgroup analysis has shown beneficial effects of
DEX implant 0.7 mg treatment on visual and anatomic
outcomes in patients with previously treated DME. Sig-
nificant improvement was seen with a mean of 4.1 DEX
implant injections over 3 years. The data suggest that
DEX implant may have a role in the treatment of DME
in the substantial number of patients who fail to respond
to standard therapy. A randomized clinical trial compar-
ing DEX implant and continued anti-VEGF therapy is
warranted to more definitively evaluate the benefit of
DEX implant treatment in anti-VEGF nonresponders.e before and after cataract surgery. Results are shown for previously
one intravitreal implant 0.7 mg group. Numbers in parentheses indicate
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